These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37370371)

  • 21. A protocol for a multicentre randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients with severe sepsis: the BLING II study.
    Dulhunty JM; Roberts JA; Davis JS; Webb SA; Bellomo R; Gomersall C; Shirwadkar C; Eastwood GM; Myburgh J; Paterson DL; Starr T; Udy AA; Paul SK; Lipman J; ;
    Crit Care Resusc; 2013 Sep; 15(3):179-85. PubMed ID: 23944203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients.
    Rafati MR; Rouini MR; Mojtahedzadeh M; Najafi A; Tavakoli H; Gholami K; Fazeli MR
    Int J Antimicrob Agents; 2006 Aug; 28(2):122-7. PubMed ID: 16815689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis: BLING III.
    Lipman J; Brett SJ; De Waele JJ; Cotta MO; Davis JS; Finfer S; Glass P; Knowles S; McGuinness S; Myburgh J; Paterson DL; Peake S; Rajbhandari D; Rhodes A; Roberts JA; Shirwadkar C; Starr T; Taylor C; Billot L; Dulhunty JM
    Crit Care Resusc; 2019 Mar; 21(1):63-68. PubMed ID: 30857514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolonged Versus Intermittent Infusion of β-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models.
    Dhaese S; Heffernan A; Liu D; Abdul-Aziz MH; Stove V; Tam VH; Lipman J; Roberts JA; De Waele JJ
    Clin Pharmacokinet; 2020 Oct; 59(10):1237-1250. PubMed ID: 32710435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic/Pharmacodynamic Target Attainment of Vancomycin, at Three Reported Infusion Modes, for Methicillin-Resistant
    Song X; Han M
    Front Cell Infect Microbiol; 2022; 12():874401. PubMed ID: 35873144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials.
    Roberts JA; Abdul-Aziz MH; Davis JS; Dulhunty JM; Cotta MO; Myburgh J; Bellomo R; Lipman J
    Am J Respir Crit Care Med; 2016 Sep; 194(6):681-91. PubMed ID: 26974879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study.
    Blot S; Koulenti D; Akova M; Bassetti M; De Waele JJ; Dimopoulos G; Kaukonen KM; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Lipman J; Roberts JA
    Crit Care; 2014 May; 18(3):R99. PubMed ID: 24887569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of a PK/PD Target of Continuous Infusion Beta-Lactams Useful for Preventing Microbiological Failure and/or Resistance Development in Critically Ill Patients Affected by Documented Gram-Negative Infections.
    Gatti M; Cojutti PG; Pascale R; Tonetti T; Laici C; Dell'Olio A; Siniscalchi A; Giannella M; Viale P; Pea F
    Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Reflections on betalactam antibiotics administered by continuous infusion].
    López E; Soy D; Miana MT; Codina C; Ribas J
    Enferm Infecc Microbiol Clin; 2006; 24(7):445-52. PubMed ID: 16956534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa.
    Pilmis B; Petitjean G; Lesprit P; Lafaurie M; El Helali N; Le Monnier A;
    Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1457-1461. PubMed ID: 31073653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolonged Infusion Piperacillin-Tazobactam Decreases Mortality and Improves Outcomes in Severely Ill Patients: Results of a Systematic Review and Meta-Analysis.
    Rhodes NJ; Liu J; O'Donnell JN; Dulhunty JM; Abdul-Aziz MH; Berko PY; Nadler B; Lipman J; Roberts JA
    Crit Care Med; 2018 Feb; 46(2):236-243. PubMed ID: 29116995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does Prolonged Infusion Time Really Improve the Efficacy of Meropenem Therapy? A Prospective Study in Critically Ill Patients.
    Zhao YC; Zou Y; Xiao YW; Wang F; Zhang BK; Xiang DX; Yu F; Luo H; Sandaradura I; Yan M
    Infect Dis Ther; 2022 Feb; 11(1):201-216. PubMed ID: 34748194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
    Sumitani Y; Kobayashi Y
    Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prolonged versus Intermittent Infusion of β-Lactams for the Treatment of Nosocomial Pneumonia: A Meta-Analysis.
    Lal A; Jaoude P; El-Solh AA
    Infect Chemother; 2016 Jun; 48(2):81-90. PubMed ID: 27433378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients.
    De Waele JJ; Lipman J; Akova M; Bassetti M; Dimopoulos G; Kaukonen M; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Udy AA; Starr T; Wallis SC; Roberts JA
    Intensive Care Med; 2014 Sep; 40(9):1340-51. PubMed ID: 25053248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review.
    Yusuf E; Spapen H; Piérard D
    J Crit Care; 2014 Dec; 29(6):1089-95. PubMed ID: 25179412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population Pharmacokinetics of Piperacillin following Continuous Infusion in Critically Ill Patients and Impact of Renal Function on Target Attainment.
    Klastrup V; Thorsted A; Storgaard M; Christensen S; Friberg LE; Öbrink-Hansen K
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32284376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Applying pharmacokinetic/pharmacodynamic measurements for linezolid in critically ill patients: optimizing efficacy and reducing resistance occurrence.
    El-Gaml RM; El-Khodary NM; Abozahra RR; El-Tayar AA; El-Masry SM
    Eur J Clin Pharmacol; 2022 Aug; 78(8):1301-1310. PubMed ID: 35610318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients?
    Roberts JA; Lipman J; Blot S; Rello J
    Curr Opin Crit Care; 2008 Aug; 14(4):390-6. PubMed ID: 18614901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infections.
    Gatti M; Pea F
    Curr Opin Infect Dis; 2021 Dec; 34(6):737-747. PubMed ID: 34261906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.